The expert panel evaluated the eye-health ingredient in accordance with FDA guidelines and found that it met the safety criteria.
Photo © iStockphoto.com/kutaytanir
OmniActive Health Technologies (Morristown, NJ) has received a notification from a panel confirming the Generally Recognized as Safe (GRAS) status of its OmniXan-RS meso-zeaxanthin ingredient. The expert panel evaluated the eye-health ingredient in accordance with FDA guidelines and found that it met safety criteria. According to the company, the OmniXan-RS ingredient (meso-zeaxanthin, or 3R,3’S zeaxanthin) is made from marigold flower and is grown and extracted through a vertically integrated supply chain. “With the rising interest and science supporting meso-zeaxanthin, OmniXan-RS helps meet a gap for a standalone RS-zeaxanthin ingredient in the market,” said Lynda M. Doyle, senior vice president of global marketing, OmniActive, in a press release. “Like most of the ingredients in our portfolio, we obtained GRAS self-affirmation to further position OmniXan-RS as unique and safe.” In addition to OmniXan-RS, the company’s range of macular carotenoids includes Lutemax 2020 lutein with enhanced zeaxanthin, Lutemax Free lutein, and OmniXan RR-zeaxanthin, made from natural paprika. Also read: Kemin's ZeaOne Zeaxanthin Gets FDA GRAS Lutein and Zeaxanthin Elicit "Rapid Retinal Response," Study Suggests The Blue-Light Message: Explaining the Benefits of Lutein and Zeaxanthin
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.